

Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-Aug-2022
 Document Type: USP Monographs
 DocId: GUID-B928D465-F8C8-45ED-80A1-EB34C6210799_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M5813_02_01
 DOI Ref: w4gbf

© 2025 USPC
 Do not distribute

Add the following:

^Cromolyn Sodium Oral Solution

DEFINITION

Cromolyn Sodium Oral Solution is a sterile solution containing NLT 90.0% and NMT 110.0% of the labeled amount of cromolyn sodium ($C_{23}H_{14}Na_2O_{11}$).

IDENTIFICATION

- **A.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Buffer: 10.0 g/L of [tetrabutylammonium hydrogen sulfate](#) in [water](#)

Mobile phase: [Acetonitrile](#) and *Buffer* (25:75)

Standard solution: 0.2 mg/mL of [USP Cromolyn Sodium RS](#) in [water](#)

Sample solution: Nominally 0.2 mg/mL of cromolyn sodium from Oral Solution prepared as follows. Mix NLT 5 containers of Oral Solution, transfer a suitable volume of the composite Oral Solution to a suitable volumetric flask, and dilute with [water](#) to volume.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 330 nm. For *Identification A*, use a diode array detector in the range of 220–400 nm.

Column: 4.6-mm × 15-cm; 5-μm packing [L1](#)

Column temperature: 30°

Flow rate: 1 mL/min

Injection volume: 20 μL

Run time: NLT 2 times the retention time of the cromolyn peak

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 1.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of cromolyn sodium ($C_{23}H_{14}Na_2O_{11}$) in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of cromolyn sodium from the *Sample solution*

r_S = peak response of cromolyn sodium from the *Standard solution*

C_S = concentration of [USP Cromolyn Sodium RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of cromolyn sodium in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

- **DELIVERABLE VOLUME (698):** Meets the requirements

IMPURITIES

• ORGANIC IMPURITIES

Solution A: 10.0 g/L of [tetrabutylammonium hydrogen sulfate](#) in [water](#)

Solution B: [Acetonitrile](#)

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	90	10
20	60	40
25	60	40
35	50	50
45	90	10
50	90	10

Diluent: [Acetonitrile](#) and [water](#) (60:40)

System suitability solution: 5 mg/mL of [USP Cromolyn Sodium RS](#) and 0.005 mg/mL each of 2-acetylresorcinol, [USP Cromolyn Related Compound A RS](#), and [USP Cromolyn Related Compound B RS](#) in *Diluent*

Sensitivity solution: 0.0025 mg/mL of [USP Cromolyn Sodium RS](#) in *Diluent*

Standard solution: 0.005 mg/mL of [USP Cromolyn Sodium RS](#) in *Diluent*

Sample solution: Nominally 5 mg/mL of cromolyn sodium from Oral Solution prepared as follows. Mix NLT 5 containers of Oral Solution, transfer a suitable volume of the composite Oral Solution to a suitable volumetric flask, and dilute with *Diluent* to volume.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 330 nm

Column: 4.6-mm × 25-cm; 5-μm packing [L1](#)

Column temperature: 30°

Flow rate: 1 mL/min

Injection volume: 20 μL

System suitability

Samples: *System suitability solution*, *Sensitivity solution*, and *Standard solution*

[NOTE—See [Table 2](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 3.0 between the cromolyn and 2-acetylresorcinol peaks; NLT 3.0 between the cromolyn related compound B and cromolyn related compound A peaks, *System suitability solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response of cromolyn from the *Standard solution*

C_s = concentration of [USP Cromolyn Sodium RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of cromolyn sodium in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.05%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Cromolyn	1.0	—
2-Acetylresorcinol ^a	1.15	0.10
Cromolyn related compound B	1.9	0.10
Cromolyn related compound A	2.1	0.10
Any unspecified impurity	—	0.10
Total impurities	—	0.5

^a 1-(2,6-Dihydroxyphenyl)ethan-1-one; also known as 2,6-Dihydroxyacetophenone.

SPECIFIC TESTS

- [STERILITY TESTS \(71\)](#): Meets the requirements
- [pH \(791\)](#): 4.0–7.0

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in light-resistant containers. Store at controlled room temperature.
- **LABELING:** The label indicates that the Oral Solution is not to be used if it contains a precipitate or is discolored.

• [USP REFERENCE STANDARDS \(11\)](#)

[USP Cromolyn Related Compound A RS](#)

1,3-Bis(2-acetyl-3-hydroxyphenoxy)propan-2-ol.



[USP Cromolyn Related Compound B RS](#)

Diethyl 5,5'-[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(4-oxo-4H-chromene-2-carboxylate).



[USP Cromolyn Sodium RS](#)▲ (USP 1-Aug-2022)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CROMOLYN SODIUM ORAL SOLUTION	Documentary Standards Support	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 45(4)

Current DocID: GUID-B928D465-F8C8-45ED-80A1-EB34C6210799_2_en-US

DOI: https://doi.org/10.31003/USPNF_M5813_02_01

DOI ref: [w4gbf](#)